Medroxyprogesterone acetate (MPA)

DRUG2 trials

Sponsors

Yamagami Wataru, University of Illinois at Chicago

Conditions

Early stage endometrial cancer and atypical endometrial hyperplasia. endometrial cancer, atypical endometrial hyperplasiaHot FlashesMenopause

Phase 2

Research Investigation of Soy and Estrogen

CompletedNCT00997893

University of Illinois at ChicagoHot Flashes, Menopause

Start: 2009-12-31End: 2015-05-31Updated: 2020-12-07

Safety and Efficacy study of repeated MPA therapy for recurrent early stage endometrial cancer patients (JGOG2051)

Active, not recruitingJPRN-jRCTs031200256

Yamagami WataruEarly stage endometrial cancer and atypical endometrial hyperplasia. endometrial cancer, atypical endometrial hyperplasia

Start: 2021-01-15Target: 115Updated: 2026-06-29

Related Papers

A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia: Japanese Gynecologic Oncology Group study (JGOG2051/KGOG2031, REMPA trial)

Journal of Gynecologic Oncology2024-01-014 citations